Brand Name
Banzel
Generic Name
Rufinamide
View Brand Information FDA approval date: November 14, 2008
Form: Tablet, Suspension
What is Banzel (Rufinamide)?
Rufinamide tablets USP are indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older, and in adults Rufinamide tablets USP are indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment